Publications by authors named "James M Orsini"
Article Synopsis
- Immune checkpoint inhibition therapy has shown promise for improving outcomes in advanced non-small cell lung cancer, but there's a need for better predictive biomarkers; a blood test called host immune classifier (HIC) was evaluated for this purpose in a real-world study.* -
- The INSIGHT study enrolled over 3,570 NSCLC patients and assessed their survival based on HIC designation (HIC-H or HIC-C) and treatment type, revealing that HIC-H patients had significantly longer overall survival compared to HIC-C patients across various treatment regimens, including ICI therapies.* -
- The findings indicate that HIC testing can independently predict patient survival outcomes regardless of the programmed death ligand 1 (PD-L1)
We hypothesized that the high early death rate (EDR) due to bleeding in acute promyelocytic leukemia (APL) is in part attributable to delays in all- trans retinoic acid (ATRA). We conducted a retrospective analysis of the timing of ATRA administration. 204 consecutive patients with newly diagnosed APL between 1992 and 2009 were identified.
View Article and Find Full Text PDF